Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Family Medicine
Disease Category: Diabetes Mellitus, Type 2
Location: United States, CA
Clinical Trial Details
Research Study Summary
TAKEDA EXAMINE trial patients for who have Type II diabetes & ACS coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin compared with placebo, in addition to standard of care, in patients with type II diabetes mellitus and acute coronary syndrome.
Patient Inclusion Criteria:
In order to participate in this study you need to have a hgA1c level between 6.5-11.0% , and a history of ACS (acute coronary syndrome) that required hospitalization with in 15-90 days prior to randomization.
Patient Exclusion Criteria:
- Signs of type I diabetes mellitus
- currently receiving a glucagon- like peptide 1 for glycemic control.
- Hemodynamically unstable cardiovascular disorder including heart failure
- Received or is receiving dialysis
- Patient has human immunodeficiency virus
- Alcohol or substance abuse
To Learn more
Both Male and Female
Date Last Changed:
July 18, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.